Observational Study of Home Administration of Carfilzomib

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

NCT03091127 ·Status: COMPLETED

Home Treatment With Carfilzomib in Patients With Multiple Myeloma

NCT05620238 ·Status: RECRUITING

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

NCT00511238 ·Status: COMPLETED ·Phase: PHASE2

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

NCT01410500 ·Status: APPROVED_FOR_MARKETING

Study on the Clinical Efficacy of Teclistamab

NCT06477783 ·Status: RECRUITING

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

NCT02597062 ·Status: COMPLETED ·Phase: PHASE2

Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma

NCT01792102 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

NCT01241396 ·Status: COMPLETED

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

NCT01949532 ·Status: COMPLETED ·Phase: PHASE1

Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone

NCT03375567 ·Status: COMPLETED ·Phase: NA

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

NCT00150462 ·Status: COMPLETED ·Phase: PHASE1

Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting

NCT05041933 ·Status: UNKNOWN

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

NCT00530816 ·Status: COMPLETED ·Phase: PHASE2

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

NCT01365559 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

NCT02020941 ·Status: TERMINATED ·Phase: PHASE2

Plan Development for Giving Teclistamab in the Outpatient Setting

NCT06251076 ·Status: RECRUITING ·Phase: PHASE4

Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients

NCT04379817 ·Status: COMPLETED ·Phase: PHASE2

UARK 2009-32 Compassionate Use Study of Carfilzomib

NCT00999414 ·Status: NO_LONGER_AVAILABLE

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584 ·Status: RECRUITING

Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib

NCT05184595 ·Status: UNKNOWN ·Phase: NA

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support

NCT02572492 ·Status: UNKNOWN ·Phase: PHASE2

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

NCT00603447 ·Status: COMPLETED ·Phase: PHASE1

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

NCT01690143 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

NCT01351623 ·Status: COMPLETED ·Phase: PHASE2